Major Depressive Disorder: key endpoint results by drug

The key endpoints of Major Depressive Disorder trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Major Depressive Disorder page.

MADRS, change (acute) (induction)

MADRS, change (acute) in Major Depressive Disorder: 9 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Ansofaxine hydrochloride-19.9a-14.6−5.3ansofaxine 160 mg · wk 8NCT04853407 Phase 3, primary
Brexpiprazole (Rexulti)-8.2-6.7−1.52 mg · wk 6 · n 245NCT03697603 Phase 2/3, primary
Cariprazine (Vraylar)-13.1-11.5−1.63 mg/Day · wk 6 · n 223NCT03738215 Phase 3, primary
Dextromethorphan/bupropion15.912.0+3.9wk 6 · n 156NCT04019704 Phase 3, primary
Esketamine-15.7-12.4−3.384 mg · wk 0.14 · n 113NCT03097133 Phase 3, primary
Lumateperone-14.7-9.8−4.942 mg · wk 6.14 · n 239NCT04985942 Phase 3, primary
Psilocybin (COMP360)-12-6.8−5.225 mg · wk 3 · n 79NCT03775200 Phase 2, primary
Seltorexant-12.9-10.5−2.420 mg · wk 6.14 · n 196NCT04533529 Phase 3, primary
Vortioxetine-15.4-12.4−3.120 mg · wk 8 · n 164NCT02389816 Phase 3, primary

Drugs checked with no result here: 9 not reported, 8 trial running, 5 not posted.

CGI-S, change (acute) (induction)

CGI-S, change (acute) in Major Depressive Disorder: 7 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Brexpiprazole (Rexulti)-0.7-0.5−0.22 mg/Day · wk 12 · n 187NCT01360645 Phase 3, secondary
Cariprazine (Vraylar)-1.3-1.1−0.23 mg/Day · wk 6 · n 223NCT03738215 Phase 3, secondary
Esketamine-2-1−184 mg · wk 4 · n 113NCT02417064 Phase 3, secondary
Lumateperone-1.6-0.9−0.742 mg · wk 6.14 · n 239NCT04985942 Phase 3, secondary
Pimavanserin-1.4-1.1−0.3wk 5 · n 148NCT03968159 Phase 3, secondary
Seltorexant-1.2-1.7 (Quetiapine XR)—wk 12 · n 38NCT03321526 Phase 2, secondary
Vortioxetine-1.4-1.3−0.120 mg · wk 8 · n 146NCT02709655 Phase 3, secondary

Drugs checked with no result here: 8 not posted, 8 not reported, 8 trial running.

MADRS response (induction)

MADRS response in Major Depressive Disorder: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Brexpiprazole (Rexulti)23.5%14.7%+8.82 mg/Day · wk 14 · n 187NCT01360645 Phase 3, secondary
Esketamine53.1%38.9%+14.284 mg · wk 4 · n 98NCT02417064 Phase 3, secondary
Seltorexant35.4%22.9%+12.520 mg · wk 6.14 · n 209NCT04533529 Phase 3, secondary
Vortioxetine50.6%36.6%+1420 mg · wk 8 · n 164NCT02389816 Phase 3, secondary

Drugs checked with no result here: 8 not posted, 10 not reported, 9 trial running.

MADRS remission (induction)

MADRS remission in Major Depressive Disorder: 3 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Brexpiprazole (Rexulti)14.4%8.4%+62 mg/Day · wk 14 · n 187NCT01360645 Phase 3, secondary
Esketamine27.1%17.6% (Quetiapine Extended Release (XR) + Oral AD)—wk 8 · n 336NCT04338321 Phase 3, primary
Vortioxetine30.9%21.1%+9.820 mg · wk 8 · n 164NCT02389816 Phase 3, secondary

Drugs checked with no result here: 8 not posted, 10 not reported, 10 trial running.

Relapse (% of patients) (maintenance)

Relapse (% of patients) in Major Depressive Disorder: 2 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Brexpiprazole (Rexulti)22.5%20.6%+1.9wk 26 · n 240NCT03538691 Phase 3, secondary
Vortioxetine15.2%30.2%−155 or 10 mg · wk 64 · n 204NCT00596817 Phase 3, secondary

Drugs checked with no result here: 8 not posted, 10 not reported, 11 trial running.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 31 approved or late-stage drugs with a featured trial in Major Depressive Disorder were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.